Company Summary

Repairogen is a Cornell Medical College spin-off that is utilizing a patented, and scientifically proven, DNA-repair technology to build a portfolio of ingredients and products focused on the large and fast-growing skincare “cosmeceuticals” market. Repairogen’s technology enhances the natural cellular DNA-repair mechanism of skin cells by impacting the activity of a specific target protein. Using its proprietary screening methodology, Repairogen has identified multiple naturally occurring compounds that are capable of significantly reducing DNA damage in the most prevalent types of human skin cells. They are now focused on completing clinical studies of their proprietary formulations and commercializing their technology in the consumer skincare market.

Year Founded:  2013

Key Executives:
• Frank Borchetta, CEO and President
• Michael Boice, PhD, Chief Scientific Officer

Location:  New York, NY

Website:  http://www.repairogen.com

Company Status:  Private

Year Invested:  2017

Investment Status:  Current